Twist Bioscience Corp (TWST) Shares Soar Above 1-Year High

Twist Bioscience Corp (NASDAQ: TWST)’s stock price has plunge by 3.27relation to previous closing price of 49.52. Nevertheless, the company has seen a -4.05% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-23 that The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033).

Is It Worth Investing in Twist Bioscience Corp (NASDAQ: TWST) Right Now?

The 36-month beta value for TWST is at 1.86. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”

The public float for TWST is 56.27M, and currently, shorts hold a 16.31% of that float. The average trading volume for TWST on January 31, 2025 was 818.28K shares.

TWST’s Market Performance

The stock of Twist Bioscience Corp (TWST) has seen a -4.05% decrease in the past week, with a 6.18% rise in the past month, and a 20.27% gain in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are at 6.20% for TWST. The simple moving average for the last 20 days is 6.31% for TWST stock, with a simple moving average of 12.46% for the last 200 days.

Analysts’ Opinion of TWST

Many brokerage firms have already submitted their reports for TWST stocks, with Wolfe Research repeating the rating for TWST by listing it as a “Outperform.” The predicted price for TWST in the upcoming period, according to Wolfe Research is $60 based on the research report published on December 13, 2024 of the previous year 2024.

Guggenheim, on the other hand, stated in their research note that they expect to see TWST reach a price target of $53. The rating they have provided for TWST stocks is “Buy” according to the report published on June 04th, 2024.

Goldman gave a rating of “Buy” to TWST, setting the target price at $45 in the report published on January 17th of the previous year.

TWST Trading at 7.65% from the 50-Day Moving Average

After a stumble in the market that brought TWST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.03% of loss for the given period.

Volatility was left at 6.20%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares surge +8.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.26% upper at present.

During the last 5 trading sessions, TWST fell by -4.05%, which changed the moving average for the period of 200-days by +66.69% in comparison to the 20-day moving average, which settled at $48.11. In addition, Twist Bioscience Corp saw 10.05% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TWST starting from Finn Patrick John, who sale 2,422 shares at the price of $50.17 back on Jan 23 ’25. After this action, Finn Patrick John now owns 272,044 shares of Twist Bioscience Corp, valued at $121,501 using the latest closing price.

Finn Patrick John, the Officer of Twist Bioscience Corp, proposed sale 2,422 shares at $50.17 during a trade that took place back on Jan 23 ’25, which means that Finn Patrick John is holding shares at $121,501 based on the most recent closing price.

Stock Fundamentals for TWST

Current profitability levels for the company are sitting at:

  • -0.71 for the present operating margin
  • 0.43 for the gross margin

The net margin for Twist Bioscience Corp stands at -0.67. The total capital return value is set at -0.41. Equity return is now at value -38.08, with -30.02 for asset returns.

Based on Twist Bioscience Corp (TWST), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -7614.9.

Currently, EBITDA for the company is -176.71 million with net debt to EBITDA at 0.8. When we switch over and look at the enterprise to sales, we see a ratio of 9.28. The receivables turnover for the company is 8.97for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.88.

Conclusion

In conclusion, Twist Bioscience Corp (TWST) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts